Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Itraconazole, Food, and pH on BMS-986368 PK
NCT06170723Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Mar 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bms-986368 in Alzheimer's disease (AD) and multiple sclerosis (MS) (6 arms), sponsored by Celgene Corporation. Primary endpoints: Maximum observed plasma concentration up to 11 days, Area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration up to 11 days and 1 more. Started Mar 2024; status: completed.
02
Drugs
bms-986368
03
Conditions
Alzheimer's disease (AD)multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06170723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06170723.